Xeris Biopharma Holdings, Inc. (XERS) reported stronger-than-expected fourth-quarter earnings and revenue, driven by its specialty pharmaceutical portfolio. The company also issued an optimistic full-year revenue forecast, signaling confidence in its commercial pipeline.
Clinical-stage biopharma Zenas BioPharma (ZBIO) is approaching a pivotal transition, with its lead drug candidate obexelimab targeting a disease with no approved therapies. While recent trial data tempered 'best-in-class' hopes, analysts see a path to significant revenue growth and a potential multi-billion dollar opportunity if commercialization succeeds.
After years of losses, Aytu BioPharma (NASDAQ: AYTU) is projected by analysts to reach breakeven by 2027 and post its first profit in 2028. The $27 million market-cap pharma firm faces a steep growth path and significant debt load on its journey to sustainability.
Twist Bioscience's proprietary silicon-based DNA manufacturing platform is driving double-digit revenue growth and margin expansion, positioning the synthetic biology tools provider on a clear path to adjusted EBITDA breakeven by fiscal 2026.
Danaher's IDBS unit has been recognized with a software innovation award at the Asia Pacific Biopharma Excellence Awards, underscoring the conglomerate's expanding footprint in high-margin, recurring-revenue digital tools alongside its traditional hardware business.
Theravance Biopharma's consensus fair value estimate has been sharply revised down by approximately 40%, refocusing investor attention on its core respiratory portfolio and balance sheet strength following the setback of ampreloxetine.
Facing a second Phase III failure for its lead candidate ampreloxetine, Theravance Biopharma announces a major strategic shift, winding down its research division and cutting half its staff to focus on revenue from existing partnered assets.
vTv Therapeutics expands its partnership with China's Newsoara Biopharma into a worldwide deal for its oral PDE4 inhibitor HPP737, receiving an immediate $20 million payment and unlocking over $100 million in potential milestones.
SOPHiA GENETICS reported a third consecutive quarter of accelerating revenue growth, driven by record customer signings and the expansion of its liquid biopsy platform. The company has raised its full-year revenue guidance, citing strong momentum across all regions and applications.
Xeris Biopharma Holdings has initiated a patent infringement lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics, aiming to block generic competition for its key drug Recorlev. The legal move comes as the company's shares trade at a significant discount to analyst targets, raising questions about its market valuation and future exclusivity prospects.
Personalis reports a 329% year-over-year surge in Q4 clinical test volume for its NeXT Personal MRD assay, fueled by recent Medicare coverage decisions in breast and lung cancer. The company sets ambitious 2026 guidance, targeting 170% volume growth and a significant shift toward prospective biopharma partnerships.
Thermo Fisher Scientific (NYSE:TMO) has secured a strong buy consensus from analysts, with a median price target suggesting significant upside. The company's resilient performance and strategic positioning in biopharma are key drivers behind the optimism.
Richard Pops, one of biotech's most enduring CEOs, will hand over leadership of Alkermes to COO Blair Jackson in July, marking a pivotal transition as the company stakes its future on promising new sleep disorder treatments.
Xbrane Biopharma reports robust revenue driven by its partnership with Stada, yet faces intensifying price competition from new market entrants. The company outlines a cost-focused strategy, delaying some initiatives to shore up margins in the volatile biosimilars landscape.
Meridian Small Cap Growth Fund's Q4 2025 letter reveals a mixed quarter for U.S. equities, with standout performance from biotech firm Zenas BioPharma following positive Phase II data. The fund's commentary provides insight into a market balancing AI optimism with economic caution.
Clinical-stage biotech Immix Biopharma (NASDAQ: IMMX) is projected to reach breakeven within two years, with analysts predicting a shift to profitability by 2028 driven by its novel cell therapy pipeline.
Buzz Bomb Caffeine Company, a subsidiary of Aspire Biopharma (ASBP), has secured a strategic partnership with Blue Shark Beverages to manage and distribute its innovative sublingual caffeine product across Southern California, beginning with a Coachella Valley launch.
Chinese biotech startup Excalipoint has raised $69 million in one of the largest early-stage financings for a domestic drug developer, fueling its pipeline of next-generation T cell engagers designed to overcome key limitations in treating solid tumors and reducing severe side effects.
Despite a turbulent 2025, Artisan Partners' Small Cap Fund highlights its continued investment in Stevanato Group (STVN), citing the company's resilient business model in the biopharma sector. The fund outperformed key benchmarks in Q4 by focusing on durable profit cycles.
Facing a longer-than-expected regulatory path and stiff competition from Pfizer's blockbuster Padcev, Bicycle Therapeutics announces a major restructuring, deprioritizing its lead ADC candidate and cutting staff to extend its financial runway.
